Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published

Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published: "THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN), today announced final results from a pivotal Phase 3 trial which showed that Vectibix™ (panitumumab), a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr), prolonged progression-free survival (PFS) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed fluoropyrimidine, irinotecan, and oxaliplatin containing chemotherapy regimens. The results were published in the May issue of the Journal of Clinical Oncology."